CN116712465A

CN116712465A - Application of bifidobacterium breve lw01 in preparation of medicines for preventing and/or treating colonitis and colonitis cancer transformation

Info

Publication number: CN116712465A
Application number: CN202310449356.2A
Authority: CN
Inventors: 王琳; 郭传瑸; 李玉珂; 田凯月; 袁若水
Original assignee: Peking University School of Stomatology
Current assignee: Peking University School of Stomatology
Priority date: 2023-04-24
Filing date: 2023-04-24
Publication date: 2023-09-08

Abstract

The invention belongs to the field of biotechnology. The invention provides an application of bifidobacterium breve B.brevelw01 in preparing a medicament for preventing and/or treating colonitis and colonitis cancer transformation. The invention also provides a medicament for treating and/or preventing colonitis and colonitis cancer transformation. The infiltration of colon macrophages is reduced by the action of bifidobacterium breve 01, and the proportion of mature macrophages in the infiltrated macrophages is increased; the specific metabolite of bifidobacterium brevelw01 can inhibit macrophage inflammatory differentiation by activating Akt signaling pathway of macrophages, and can also inhibit inflammatory cancer transformation by modulating intestinal lamina propria macrophage differentiation. The role play of bifidobacterium breve lw01 depends in part on the regulation of intestinal flora.

Description

Application of bifidobacterium breve lw01 in preparation of medicines for preventing and/or treating colonitis and colonitis cancer transformation

Technical Field

The invention relates to the field of biotechnology, in particular to application of bifidobacterium breve lw01 in preparation of a medicament for preventing and/or treating colonitis and colonitis cancer transformation.

Background

Colorectal cancer is the third most common cancer and is also one of the leading cancers leading to death. In recent years, the age of occurrence of colorectal cancer has assumed a gradually younger situation. Chronic inflammation is one of the major causes of colorectal cancer occurrence. Reactive Oxygen Species (ROS) and pro-inflammatory cytokines released by immune cells mutate and accelerate the cancerous progression of intestinal epithelial cells during the tumorigenic stage. Colorectal cancer associated with colitis is a typical disease that develops from inflammatory bowel disease (including crohn's disease and ulcerative colitis). Improving the inflammatory response of the intestinal tract has become a potential method for preventing inflammation-associated colorectal cancer.

The gut microbiota and its metabolites have a central impact on establishing gut homeostasis. In recent years, such as Acremonium, bifidobacterium, lactobacillus and the like are considered to play a key role in regulating intestinal immune response. Wherein, the bifidobacterium is taken as a first microbial community planted in the intestinal tracts of infants, and can play roles in regulating host immune response, relieving allergic symptoms and treating inflammatory diseases. It is well known that the development of bacterial action is strain specific. Different strains and combinations will exhibit different degrees of remission. Bifidobacterium breve lw01 isolated from the infant gut has been shown in published studies by the inventors to promote recruitment of intestinal cd11b+cd103-dendritic cells to promote IL-12 secretion, activate T cells to inhibit growth of subcutaneous tumors. On the basis, the bifidobacterium breve lw01 is further explored, and whether the strain has a certain significance in the aspects of inflammatory cancer transformation and the like is explored.

Disclosure of Invention

The invention aims to provide an application of bifidobacterium breve lw01 in preparing a medicament for preventing and/or treating colonitis and colonitis cancer transformation, wherein the infiltration of colonic macrophages is reduced and the proportion of mature macrophages in the infiltrated macrophages is increased under the action of the bifidobacterium breve lw 01; the specific metabolite indoleacetic acid of bifidobacterium breve lw01 can inhibit macrophage inflammatory differentiation by activating an Ak signal pathway of macrophages, and can also effectively inhibit inflammatory cancer transformation by regulating intestinal lamina propria macrophage differentiation. The role play of bifidobacterium breve lw01 depends in part on the regulation of intestinal flora.

In order to achieve the above object, the present invention provides the following technical solutions:

the invention provides an application of bifidobacterium breve lw01 in preparing a medicament for preventing and/or treating colonitis.

Preferably, the bifidobacterium breve lw01 has been preserved in the China general microbiological culture Collection center of China Committee for culture Collection of microorganisms, including China general microbiological culture Collection center No.1 and No. 3 of North Chenxi Lu of the Korean area of Beijing, and the preservation number is CGMCC No.17727.

The invention also provides an application of the bifidobacterium breve lw01 in preparing a medicament for preventing and/or treating colonitis cancer transformation.

The invention also provides a medicine for treating and/or preventing colonitis and colonitis cancer transformation, which comprises the bifidobacterium breve lw01.

Preferably, the medicament is a liquid formulation.

Preferably, the concentration of Bifidobacterium breve lw01 in the medicament is (0.5-1.2). Times.10 ⁹ CFU/100μL。

By adopting the technical scheme, the invention has the following beneficial effects:

1. in the invention, bifidobacterium breve lw01 can reduce the infiltration of colon macrophages, and the proportion of immature macrophages in the infiltrated macrophages is reduced, and the proportion of mature macrophages is increased.

2. The bifidobacterium breve lw01 can promote the differentiation of immature colon macrophages to the direction of inflammation-inhibiting macrophages by generating specific metabolite indolyl lactic acid, and can also inhibit the inflammatory differentiation of macrophages by activating an Akt signal path of the macrophages, thereby regulating the local immune microenvironment of intestinal tracts, and improving the intestinal tract environment of premalignant inflammation to achieve the effect of inhibiting tumor generation.

Drawings

FIG. 1 shows the colon condition of the mouse AOM/DSS model (A in FIG. 1 is the flow chart for constructing the AOM/DSS cancer transformation model; B in FIG. 1 is the colon length condition; C in FIG. 1 is the size of colon tumor; D in FIG. 1 is the number of colon tumors);

FIG. 2 is a graph showing changes in the colonic lamina propria macrophage population in mice; (A in FIG. 2 is the phylum of the mouse colon lamina propria marrow system cell ring analyzed by flow cytometry; B in FIG. 2 is the proportion of macrophages in leukocytes; C in FIG. 2 is the proportion of immature macrophages P1 in the colon lamina propria; D in FIG. 2 is the proportion of P2 in the macrophages; E in FIG. 2 is the proportion of mature macrophages P3 in the colon lamina propria);

FIG. 3 shows the colon condition of the AOM/DSS model after mouse macrophage knockdown (A in FIG. 3 is a flow chart for constructing the macrophage knockdown model; B in FIG. 3 is the length of colon; C in FIG. 3 is the size of colon tumor; D in FIG. 3 is the number of colon tumors);

FIG. 4 shows the amount of macrophages and the subtype of the changes after mouse macrophage knockdown; (A in FIG. 4 is the loop gate strategy of macrophage typing; B in FIG. 4 is the proportion of macrophages in leukocytes; C in FIG. 4 is the proportion of immature macrophages P1 in the colon lamina propria; D in FIG. 4 is the proportion of P2 in macrophages; E in FIG. 4 is the proportion of mature macrophages P3 in the colon lamina propria;

FIG. 5 shows the results of transcriptome sequencing of the colon lamina propria macrophages (A in FIG. 5 is a volcanic chart of the differential expression genes of the colon lamina propria macrophages transcriptome; B in FIG. 5 is the differential expression genes of the colon lamina propria macrophages related to inflammation, chemotaxis and macrophage differentiation; C in FIG. 5 is the differential gene up-regulated by KEGG enrichment analysis; D in FIG. 5 is the molecular function of the GO pathway of the down-regulated expression genes; E in FIG. 5 is the biological pathway of the GO pathway of the down-regulated expression genes);

FIG. 6 is a graph of flora metabolite association analysis looking for differential metabolites; (A in FIG. 6 is a microbial richness index analysis of intestinal flora OTU; B in FIG. 6 is a PCA graph of B.breve lw01 in bifidobacterium breve for regulating beta diversity in the intestinal flora of mice; C in FIG. 6 is a PCoA graph of beta diversity for measuring microbial composition; D in FIG. 6 is a scatter plot of genus level differential bacteria; E in FIG. 6 is a classification tree of different species between two groups based on LEfSe; F in FIG. 6 is a thermal graph of differential metabolites in different groups of feces; G in FIG. 6 is a thermal graph of LC-MS/MS, H in FIG. 6 is a content of ILA in different groups of feces; I in FIG. 6 is a plot of ILA content in percent versus beta diversity in feces; J in FIG. 6 is a scatter plot of B.breve and beta metabolism metabolites between MRS supernatant; K in FIG. 6 is a graph of B.breve lw01 culture fluid and beta diversity in MRS supernatant; L in FIG. 6 is a graph of the in vitro concentration of the bacteria reported after the two groups of beta metabolism protein in vitro);

FIG. 7 shows the expression changes of the AhR receptor activation related genes Cyp1α1, cyp1b1 and Cyp1α2 in colon tissue of AOM/DSS mouse model (A in FIG. 7 is the expression of the gene Cyp1α1, B in FIG. 7 is the expression of the gene Cyp1b1, C in FIG. 7 is the expression of the gene Cyp1α2);

FIG. 8 shows the expression changes of AhR receptor activation related genes Cyp1α1, cyp1b1 and Cyp1α2 in colon macrophages of AOM/DSS model mice;

FIG. 9 is a flow cytometry analysis of the effect of ILA and inhibitor CH-223191 on CD86 and CD206 expression following bone marrow-derived macrophage (BMDM) (A in FIG. 9 is the effect on CD86 expression, B in FIG. 9 is the effect on CD206 expression);

FIG. 10 shows Western blotting of the relevant pathways after ILA and AKT inhibitors act on bone marrow primary macrophages (A in FIG. 10 shows Western blotting; B in FIG. 10 shows relative phosphorylation under various actions);

FIG. 11 shows the colon condition of the mouse AOM/DSS inflammatory carcinoma transformation model under the action of ILA and its inhibitor CH-223191 (A in FIG. 11 is the flow chart of the construction of the model under the action of ILA and its inhibitor AOM/DSS inflammatory carcinoma transformation model; B in FIG. 11 is the length of colon; C in FIG. 11 is the size of colon tumor; D in FIG. 11 is the number of colon tumors);

FIG. 12 shows the results of flow cytometry for the construction of a mouse AOM/DSS cancer transformation model with ILA and its inhibitor CH-223191 (A in FIG. 12 is the proportion of macrophages in leukocytes; B in FIG. 12 is the P1 subclass in macrophages; C in FIG. 12 is the proportion of P2 subclass in macrophages; D in FIG. 12 is the proportion of P3 subclass in macrophages);

FIG. 13 shows the colon condition of a model for constructing a mouse AOM/DSS inflammatory cancer transformation by using bifidobacterium B.breve lw01 and ILA inhibitor CH-223191 (A in FIG. 13 shows the flow chart for constructing the model for constructing the AOM/DSS inflammatory cancer transformation by using bifidobacterium B.breve lw01 and ILA inhibitor CH-223191; B in FIG. 13 shows the length of colon; C in FIG. 13 shows the size of colon tumor; and D in FIG. 13 shows the number of colon tumors);

FIG. 14 shows the results of flow cytometry for constructing a mouse AOM/DSS cancer transformation model using Bifidobacterium B.breve lw01 and ILA inhibitor CH-223191 (A in FIG. 14 is the proportion of macrophages in leukocytes, B in FIG. 14 is the proportion of P1 in macrophages, C in FIG. 14 is the proportion of P2 in macrophages, and D in FIG. 14 is the proportion of P3 in macrophages).

Description of biological preservation

The bifidobacterium breve lw01 provided by the invention is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) on the 05 th month 08 in 2019, and the preservation address is the North Chen West Lu No.1, 3 of the Korean region of Beijing city, and the preservation number is CGMCC No.17727.

Detailed Description

In the invention, the bifidobacterium breve lw01 is preserved in the China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) on the 05 th month 08 of 2019, and the preservation address is the number 3 of the North Chen West Lu 1 of the Korean area of Beijing, and the preservation number is CGMCC No.17727.

The invention provides an application of bifidobacterium breve lw01 in preparing a medicament for preventing and/or treating colonitis cancer transformation.

In the present invention, the drug is a liquid preparation.

In the present invention, the concentration of B.breve lw01 of the bifidobacterium breve in the medicament is preferably (0.5-1.2). Times.10 ⁹ CFU/100. Mu.L, further preferably (0.8-1.1). Times.10 ⁹ CFU/100. Mu.L, more preferably 1X 10 ⁹ CFU/100μL。

The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.

Example 1

(one)

Bifidobacterium breve lw01 was cultured in Man Rogosa and Sharpe (MRS) medium (available from Beijing land bridge technologies Co., ltd.) and 20g/L raffinose (available from Solarbio) and 2.5 g/LL-cysteine (available from Sigma-Aldrich) were added to the medium, anaerobically cultured at 37℃for 24 hours, and then centrifuged at 4000rpm for 10 minutes, followed by collection of cells. Adding sterilized PBS buffer solution into thallus to obtain final product with concentration of 1×10 ⁹ CFU/100. Mu.L of cell suspension.

(II)

The experiment selects 32C 57BL/6 mice (purchased from Experimental animal technologies Co., ltd., beijing, vitrenlhua) of 6 weeks old, all mice are randomly divided into 4 groups of 8 mice after 1 week adaptation in the experimental environment, and intestinal flora normalization is performed. Under specific pathogen-free conditions, mice were kept at room temperature (22 ℃ ±2 ℃) for 12/12 hours of day/night circulation.

By means of azomethane (AOM, from Sigma-Aldrich) and dextran sulfateSodium (DSS, available from MP Biomedicals) was used to establish a model of transformation of mouse colitis carcinoma. Mice were intraperitoneally injected with AOM, initially dosed at 10mg/kg body weight, and after one week mice were continuously fed with water containing 2% dss for 7 days, followed by normal water for another 14 days, and the cycle was repeated two more times (as in a in fig. 1). The constructed AOM/DSS cancer transformation model mice were then fed orally PBS (100. Mu.L/d) and bifidobacterium breve lw01 (1X 10), respectively ⁹ CFU/100. Mu.L/d), two groups of PBS and Bifidobacterium breve lw01 were obtained.

One PBS group and bifidobacterium breve lw01 group were sacrificed separately on day 70 and day 91, resulting in 4 groups of mouse models at both time points. The abdominal cavity was opened, colon tissue was isolated, and the length of the colon, the number of colon tumors, and the size were measured. As a result, as shown in B-D of FIG. 1, the colon length of the B.breve lw01 group of Bifidobacterium breve was decreased, and the number of tumors was significantly decreased, regardless of the day 70 or the day 91.

(III)

Intestinal lamina propria immune cells are isolated from colon tissue. Colonic tissue was dissected, the fat fraction was discarded and washed with PBS. The colon tissue was then shaken in a solution containing 10mM HEPES (from Solarbio) and 1mM DTT (from Sigma-Aldrich) at 37℃for 10min at 250rpm, and rapidly manually for 2min. The tissue was then transferred to PBS containing 30mM EDTA (from Solarbio) and continued to dissociate, again with shaking at 250rpm for 10min at 37℃and manually with rapid shaking for 2min. Dissociated tissue was transferred to RMPI-1640 medium containing 10% FBS, gently inverted for 2min, and then transferred to RMPI-1640 digest containing 300U/mL collagenase VIII (from Sigma-Aldrich), 0.15mg/mL DNase I (from Sigma-Aldrich) and 10% FBS, and placed in 5% CO ₂ Digestion is carried out for 90min at 37 ℃ in an incubator. The digested tissue was filtered through a 70 μm sieve and the solution was centrifuged at 500g for 5min at room temperature to collect the cells. Finally, the pellet was resuspended in 4ml of 40% Percoll solution, 2.5ml of 80% Percoll solution was added dropwise to the bottom of the centrifuge tube, and the pellet was centrifuged at 1000g for 20min at room temperature (1-liter, 0). After centrifugation, the isolated cells were resuspended in FACS buffer and blocked with anti-CD 16/CD32 mAbFc-gamma receptor. Staining cells with antibodies directed against CD45, CD11b, F4/80, ly6G, siglec-F, CD11C, MHCII, ly 6C; dead cells were identified by 7-AAD staining and the specific selected antibodies are shown in Table 1.

Flow cytometry was performed on BD FACSymphony S6 and data was analyzed using flowjo_v10.8.1.

TABLE 1 antibody Condition for use with different immunocytes

Cells of the mouse colon lamina propria myeloid line were obtained by using the flow cytometry analysis described above, as a in fig. 2. In addition, through analysis of the data (as shown in B-E in FIG. 2), the proportion of macrophages in the B.breve lw01 group of white blood cells of bifidobacterium breve was significantly reduced, and the proportion of pro-inflammatory macrophages P1 (CD 45) in the macrophages ⁺ CD11b ⁺ F4/80 ⁺ Ly6G ^- Siglec-F ^- CD11c ^- Ly6C ^hi MHCII ^- ) And intermediate macrophage P2 (CD 45) ⁺ CD11b ⁺ F4/80 ⁺ Ly6G ^- Siglec-F ^- CD11c ^- Ly6C ⁺ MHCII ⁺ ) Is also significantly reduced, while the anti-inflammatory macrophage P3 (CD 45) ⁺ CD11b ⁺ F4/80 ⁺ Ly6G ^- Siglec-F ^- CD11c ^- Ly6C ^- MHCII ⁺ ) The proportion of pro-inflammatory macrophages is relatively increased, i.e. the proportion of pro-inflammatory macrophages is reduced and the proportion of anti-inflammatory macrophages is increased. This also indicates that intake of bifidobacterium breve lw01 reduces infiltration of colon lamina propria macrophages and promotes maturation and differentiation of colon macrophages.

Example 2

And (5) constructing a mouse macrophage knockdown model. Mice were intraperitoneally injected with AOM, initially dosed at 10mg/kg body weight, and simultaneously fed orally with PBS (100. Mu.L/d) and bifidobacterium breve B.breve lw01 (1X 10) ⁹ CFU/100. Mu.L/d), two groups of PBS and Bifidobacterium breve lw01 were obtained.

After that, the Chlorophosphonate Liposomes (CLD) and Veh were injected by tail vein injection, respectively, 100 μl/every three days, to obtain two groups each of CLD group and Veh group. After one week, mice were continuously fed with water containing 2% dss for 7 days, and finally pbs+veh group, bifidobacterium breve lw01+veh group, pbs+cld group, and bifidobacterium breve lw01+cld group (as in a in fig. 3) were obtained.

Length of colon, number of colon tumors, and size

Four groups of mice were sacrificed on day 28, the abdominal cavity was opened, colon tissue was isolated, and the length of the colon, the size of the colon tumor, and the number of colon tumors were measured. The results are shown in FIG. 3B-D, wherein the colon length of the B.breve lw01+Veh group is increased relative to the PBS+Veh group, and the protective effect of B.breve lw01 on the colon after the CLD knockdown of macrophages is lost, which is shown by no statistical difference between the colon length of the B.breve lw01+CLD group and the PBS+CLD group. Colon tumors in pbs+veh group were relatively maximal, bifidobacterium breve lw01 group had significantly reduced tumor size and tumor number. However, colon tumor size and number were not different in PBS group and b.breve lw01 group after CLD clearance of macrophages. The above results suggest that b.brevelwa 01 reduces colonic inflammation and that the phenotypic effects of delaying inflammatory cancer transformation are dependent on macrophages.

(II) flow cytometry experiments of intestinal lamina propria immune cells

The intestinal lamina propria immune cells of this example were also analyzed by flow cytometry as described in example 2, and infiltration of the mice after knockdown of macrophages in the colon lamina propria was observed, as shown in FIG. 4B. There was no statistical difference in the proportion of macrophages in the CLD group and bifidobacterium breve lw01+cld group leukocytes after CLD knockdown compared to b.breve lw01, which was effective in reducing macrophage numbers. Macrophage subclass analysis it was seen that the effect of the bifidobacterium breve lw01+veh group on pro-inflammatory P1 subclass macrophages was reduced and that the effect of anti-inflammatory P3 subclass macrophages elevation was lost after CLD knockdown. (as in FIGS. 4B-E). This further demonstrates that the effect of bifidobacterium breve lw01 in inhibiting inflammatory cancer transformation is dependent on macrophages.

Example 3

Based on bifidobacterium breve lw01 in example 1. Total RNA from intestinal macrophages isolated from fresh tissue by flow cytometry was extracted using TRIzol reagent. RNA-Seq library construction cDNA amplification was used by SMART in combination with transposase-based library construction techniques. The single-stranded circular DNA molecules are replicated by rolling circle amplification to produce DNA Nanospheres (DNBs) containing multiple DNA copies. DNBs of sufficient quality are then loaded into the patterned nanoarrays using high intensity DNA nanochip technology and sequenced by combined probe-anchored synthesis (cPAS). Sequencing data was filtered with SOAPnuke, after which clear reads were obtained and stored in FASTQ format. Subsequent analysis and data mining was performed on a Dr.Tom multiple-composition data mining system (https:// biosys.bgi.com).

The results of transcriptome sequencing of the macrophages of the colon lamina propria are shown in fig. 5, and the bifidobacterium breve lw01 is found to significantly influence the expression of differential genes related to the macrophages of the colon lamina propria, including genes related to inflammation, chemokines and differentiation. And further, the bacteria can regulate PI3K/Akt channels of intestinal lamina propria macrophages through KEGG and GO channel enrichment.

Example 4

(one) 16S rRNA sequencing

Based on bifidobacterium breve lw01 and PBS group in example 1. Colon faeces of each group of mouse models were taken as samples, microbial DNA of each sample was extracted, and then 16S rRNA was amplified in V3-V4 hypervariable region. These libraries were sequenced on the NovaSeq PE250 platform. And (3) carrying out mass filtration on the rawreads under specific filtration conditions according to fqtrim to obtain high-quality clean tags, and filtering the chimeric sequences by using Vsearch software. After deduplication, a feature table and sequence are obtained. Amplicon Sequence Variants (ASV) is used to construct an Operational Taxon (OTU) to obtain the final ASV feature table and sequence. The data were analyzed in an on-line platform (https:// www.omicstudio.cn/index).

The results are shown in fig. 6 a-F, and no significant differences in b.breve lw01 group α diversity were found (a in fig. 6), but significant changes in β diversity (B-E in fig. 6), suggesting that bifidobacteria uptake significantly altered the composition of the flora relative to the PBS group. The abundance change of bifidobacteria of the bifidobacterium group was most pronounced (F in fig. 6).

(II) high Performance liquid chromatography-tandem Mass Spectrometry (LC-MS/MS) analysis

Differential metabolites of AOM/DSS cancer transformation model mice were studied. The content of the colon of the sacrificed mice is weighed 1-2g, immediately placed in a sterile sampling box, and frozen and preserved at-80 ℃ to be taken as a sample. After thawing frozen samples, homogenizing, weighing the colon content of each sample by 50+ -1 mg in a 2mL EP tube, adding steel balls, adding 1000 μl of precooled extraction liquid methanol: acetonitrile: water=2:2:1 (containing internal standard ribitol); treating for 4min by a 35Hz grinding instrument, and performing ice water bath ultrasonic treatment for 5min (repeating for 3 times); standing in a refrigerator at the temperature of minus 40 ℃ for 1 hour; the sample was centrifuged at 4℃and 12000rpm (centrifugal force 13800g, radius 8.6 cm) for 15min; 200. Mu.L of supernatant was carefully removed in a 1.5mLEP tube and 100. Mu.L of each sample was mixed into QC samples; drying the extract in a vacuum concentrator; adding 40 mu L of methoxyamine salt reagent (methoxyamine hydrochloride, dissolved in 20mg/mL of pyridine) into the dried metabolite, slightly mixing, and placing into an oven for incubation at 80 ℃ for 30min; to each sample 50. Mu.L BSTFA (containing 1% TMCS, v/v) was added and the mixture incubated at 70℃for 1.5h; cooled to room temperature, 5 μl FAMEs (dissolved in chloroform) was added to the mixed sample; and (5) randomly and sequentially starting up for detection. The instrument is an Agilent 7890 gas chromatograph-time-of-flight mass spectrometer. Analysis of peak extraction, baseline correction, deconvolution, peak integration, peak alignment, etc. was performed on the mass spectrum data using ChromaTOF software (v4.3x, LECO). Qualitative characterization of the material, LECO-fiehn rtx5 database was used, including mass spectrum matching and retention time index matching. Finally, peaks with detection rate below 50% or RSD > 30% in QC samples are removed. Raw data was converted to mzXML format using Proteowizard and processed using an internal program developed using R and XAMS based for peak detection, extraction, alignment and integration. The internal MS2 database (biotredb) was then applied to metabolite annotation.

The results are shown in G-I in FIG. 6, and the content of the metabolite indoleacetic acid (ILA) in the B.breve lw01 group of bifidobacterium breve is found to be significantly increased, and the ILA and the abundance of bifidobacterium are significantly positively correlated.

(III)

The culture supernatant of bifidobacterium breve lw01 (BCS) was studied for L-tryptophan and its downstream metabolites.

Taking a BCS culture solution and an MRS supernatant as liquid samples respectively, taking 100 mu L of each sample, adding 400 mu L of extracting solution (methanol: acetonitrile=1:1, precooling at-40 ℃ C., and containing 0.1% of formic acid and isotope-labeled internal standard mixture); vortex for 30s, ultrasonic for 5min under ice water bath condition; standing the sample at-40 ℃ for 1h; the sample was centrifuged at 12000rpm at 4℃for 15min; taking 400 mu L of supernatant, drying with nitrogen, and re-dissolving 100 mu L of aqueous solution containing 0.1% formic acid; centrifuge at 12000rpm for 15min at 4℃and collect supernatant for UHPLC-MS-MS analysis. UHPLC separation was performed using the EXIONLC system (Sciex), SCIEX 6500QTRAP+ triple quadrupole mass spectrometer (Sciex) equipped with an IonDrive Turbo V electrospray ionization (ESI) interface for analytical development. The results are shown in J-L of FIG. 6, which shows that the ILA concentration of the BCS culture broth group is significantly higher than that of the MRS supernatant group.

The analysis of the flora in FIG. 6 shows that the B.breve lw01 group of bifidobacterium breve is significantly enriched in the abundance of some probiotics (e.g., anaerostics, eubacterium, fabricius, megamonas) and reduced in some potential pathogenic species associated with colon cancer carcinogenesis (Parabacterium parapsilosis, peptostreptococcus). These bacteria have been reported to be associated with tryptophan metabolites, suggesting that the effect of the bifidobacterium breve lw01 group on ILA content may be partly achieved by modulating intestinal microbial composition.

Taken together, it can be seen that the metabolite with the most obvious difference in the b.breve lw01 group of bifidobacterium breve was indoleacetic acid, i.e. it is suggested that b.breve lw01 of bifidobacterium breve may exert an effect of inhibiting inflammatory cancer transformation by secreting indoleacetic acid. Further validation is performed in the following examples.

Example 5

RNA isolation and real-time quantitative PCR (qRT-PCR)

Total RNA was extracted from fresh colon tissue of AOM/DSS cancer transformation model mice of example 1 using TRIzol reagent (Thermo Fisher). Composition of qRT-PCR reaction system: 2 XSYBR 10. Mu. L, cDNA 1. Mu.L, primer mix 1. Mu. L, nuclear-free water 8. Mu.L. Conditions of qRT-PCR: pre-denaturation at 95℃for 10min, denaturation (15 s at 95 ℃), annealing and extension (1 min at 60 ℃). The primer sequences are shown in Table 2.

TABLE 2 primer sequences

mRNA expression was quantified using SYBR Green (Roche) on qRT-PCR system (Applied Biosystems). The results are shown in FIG. 7 for more expression of Cyp1a1, cyp1b1 and Cyp1α2 in groups A-C, B.breve lw01. The expression of the AhR receptor activation related genes Cyp1a1, cyp1b1 and Cyp1α2 in mouse colon macrophages was obtained by RNAseq results of example 1, see in particular FIG. 8.

(II)

Bone marrow derived macrophages (bone marrow-derived macrophages, BMDM) were isolated and cultured. BMDMs were differentiated from femur and tibia bone marrow cells (BMs) of the 6-week-old male C57BL/6 mice described in this experiment. BM in Roswell Park Memorial Institute 1640 (RPMI-1640) medium (available from Gibco) at 37℃under 5% CO ₂ Culture in 95% air for 5 days to differentiate into BMDMs, 10% FBS (from Sigma-Aldrich), 1% penicillin/streptomycin (from Gibco) and 30ng/ml M-CSF (from BioLegend) were also added to the medium. Medium was replenished every two days. Non-adherent cells were removed by washing with PBS. After 5 days, harvest from>Adherent cells consisting of 95% f4/80+ macrophages.

1. Pro-inflammatory differentiation of bone marrow primary macrophages

For inflammatory macrophage differentiation, BMDMs were stimulated with 100ng/mL LPS for 24h. In the ILA group, BMDMs were treated with 500. Mu.M or 1000. Mu.M ILA for 12h. In rescue experiments, BMDMs were stimulated with 100ng/mL LPS for 24h, followed by the addition of 10 μMCH-223191 (AhR agent, available from sigma) for 1h, and finally ILA was treated with 500 μM or 1000 μM for 12h.

2. Flow cytometry

BMDMs were subjected to the same flow cell experiment, and after completion, cells were collected by washing with PBS, stained for surface markers CD86 and CD206, and dead cells were identified by staining with 7-AAD. Flow cytometry was also performed on BD FACSymphony S6, and data analysis was performed by flowjo_v10.8.1.

TABLE 3 antibody Condition for different immunocytes

As a result, it was found (see A-B in FIG. 9) that ILA could inhibit the pro-inflammatory differentiation of bone marrow primary macrophages, and that there was no statistical difference in this effect after AhR receptor inhibition relative to the control group.

3. Western immunoblotting

BMDM protein was extracted using RIPA buffer (available from Yu Huaxing organism) containing protease inhibitor and phosphatase inhibitor. Proteins were separated on 10% SDS-PAGE, transferred to PVDF membrane, blocked with 5% skimmed milk for 1h and incubated overnight at 4℃with primary antibody. Subsequently, the membranes were incubated with horseradish peroxidase-conjugated corresponding species secondary antibodies for 1h. The signals were visualized using ECL enhancement kit. The output image was analyzed using ImageJ software.

TABLE 4 antibody Condition for different immunocytes

From the results of this experiment (see a-B in fig. 10), ILA can promote phosphorylation of bone marrow primary macrophage Akt. The effect on Akt phosphorylation is lost following the action of an AhR receptor inhibitor.

Overall, the ILA activating receptor AhR receptor relieves LPS-induced BMDM pro-inflammatory responses by activating Akt signaling.

Example 6

Similarly, 24 6 week old C57BL/6 mice were selected, all mice were randomized into 3 groups of 8 mice each after 1 week adaptation in the experimental environment, and intestinal flora normalization was performed. Under specific pathogen-free conditions, mice were kept at room temperature (22 ℃ ±2 ℃) for 12/12 hours of day/night circulation. The mice were then intraperitoneally injected with AOM on day 0, initially dosed at 10mg/kg body weight, and given PBS (100. Mu.L/day, oral) and ILA (20 mg/kg/day, oral, available from MedChenExpress) for a period of 91 days following the procedure described for A in FIG. 11. The mice were fed continuously with water containing 2% dss for 7 days after one week, followed by normal water for another 14 days, and the cycle was repeated two more times. And CH-223191 (10 mg/kg/every two days) was injected by intraperitoneal injection from day 0, to finally obtain PBS group, ILA group and ILA+CH-223191 group.

Length of colon, number of colon tumors, and size

The three groups of mice were sacrificed on day 91, the abdominal cavity was opened, colon tissue was isolated, and the length of the colon, the size of the colon tumor, and the number of colon tumors were measured. As shown in FIGS. 11B-D, the ILA group had the longest colon length, the smallest tumor diameter, and the smallest tumor number. After addition of the CH-223191 inhibitor, the protective effect of ILA on colon tissue was lost. This indicates at the animal level that the effect of ILA in inhibiting inflammatory cancer transformation is lost after the effect of AhR receptor inhibitor.

(II) flow cytometry

Flow cytometry and various indices are the same as in embodiment 1.

As can be seen from FIGS. 12A-D, the proportion of macrophages in the ILA group of leukocytes is relatively lowest and the proportion of macrophages in the PBS group of leukocytes is relatively highest; ahR inhibitor CH-223191 restored the fraction of macrophages in leukocytes. The proportion of P1 in the ILA group macrophages was reduced relative to the PBS group, the proportion of P3 was increased, and the effect of ILA on the regulation of the proportion of P1 and P3 was lost after the action of AhR inhibitor CH-223191. This indicates in animal models that the ability of ILA to modulate the direction of macrophage differentiation is substantially lost following the action of AhR receptor inhibitors.

In conclusion, the indole lactic acid can regulate the differentiation of mouse intestinal lamina propria macrophages through AhR receptors to play a role in inhibiting inflammation and inhibiting inflammatory cancer transformation.

Example 7

Similarly, 32 6 week old C57BL/6 mice were selected, all mice were randomized into 4 groups of 8 mice each after 1 week adaptation in the experimental environment, and intestinal flora normalization was performed. Under specific pathogen-free conditions, mice were kept at room temperature (22 ℃ ±2 ℃) for 12/12 hours of day/night circulation. And then proceeds according to the operation described in a in fig. 13. On day 0, mice were intraperitoneally injected with AOM, initially dosed at 10mg/kg body weight, and PBS (100. Mu.L/day, oral) and B.breve lw01 (1X 10) ⁹ CFU/100. Mu.L/d) was collected for 91 days. The mice were fed continuously with water containing 2% dss for 7 days after one week, followed by normal water for another 14 days, and the cycle was repeated two more times. And CH-223191 (10 mg/kg/every two days) was injected intraperitoneally from day 0 to finally obtain PBS+Veh group, bifidobacterium breve lw01+Veh group, PBS+CH-223191 group, and Bifidobacterium breve lw01+CH-223191 group.

Length of colon, number of colon tumors, and size

Four groups of mice were sacrificed on day 91, the abdominal cavity was opened, colon tissue was isolated, and the length of the colon, the size of the colon tumor, and the number of colon tumors were measured. As a result, as shown in B-D of FIG. 13, the length of the colon in the B.breve lw01+Veh group was relatively longest, and the protective effect of the B.breve lw01+CH-223191 group on the colon was lost after the inhibitor was added. The colon tumor diameter of the B.breve lw01+Veh group is minimum and the number is minimum, and the colon tumor number and size of the B.breve lw01+CH-223191 group are increased. This also indicates that the effect of bifidobacterium breve lw01 on inhibiting inflammatory cancer transformation is lost after the action of AhR receptor inhibitor.

(II) flow cytometry

Flow cytometry and various indices are the same as in embodiment 1.

As can be seen from FIG. 14A-D, the proportion of macrophages in the B.breve lw01+Veh group of white blood cells of bifidobacterium breve was relatively minimal, the proportion of P1 in the macrophages was relatively low, the proportion of P3 was relatively high, and the total amount of macrophages in the B.breve lw01+CH-223191 group of bifidobacterium breve was increased over the B.breve lw01 group, with the P1 gate being raised relative to the B.breve lw01 group and the P3 gate being relatively reduced. This also indicates that bifidobacterium breve lw 01's ability to modulate macrophage differentiation direction was substantially lost following AhR receptor inhibitor action.

In conclusion, bifidobacterium breve lw01 can regulate the differentiation of mouse intestinal lamina propria macrophages through AhR receptors to play a role in inhibiting inflammation and inhibiting inflammatory cancer transformation.

From the above examples, the invention can reduce the infiltration of colon macrophages and increase the proportion of mature macrophages in the infiltrated macrophages by the action of bifidobacterium breve lw 01; the specific metabolite indoleacetic acid of bifidobacterium breve lw01 can inhibit macrophage inflammatory differentiation by activating an Akt signal pathway of macrophages, and can also effectively inhibit inflammatory cancer transformation by regulating intestinal lamina propria macrophage differentiation. The role play of bifidobacterium breve lw01 depends in part on the regulation of intestinal flora.

The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.

Claims

1. Use of bifidobacterium breve-low01 in the manufacture of a medicament for the prevention and/or treatment of colitis.

2. The use according to claim 1, wherein the bifidobacterium breve b.brevelw01 has been deposited at the China general microbiological culture Collection center with the accession number cgmccno.17727 at the national institute of microbiological culture collection center, 05, and at the accession number of the institute of microbiological culture, national institute of sciences, north chen, and west road No.1, 3, of the region of korea, beijing.

3. Use of bifidobacterium breve-low01 in the manufacture of a medicament for the prevention and/or treatment of conversion of colitis cancer.

4. A medicament for the treatment and/or prophylaxis of colitis and of cancerous transformations of colitis, characterized in that it comprises bifidobacterium breve elw01 according to claim 1.

5. The medicament of claim 4, wherein the medicament is a liquid formulation.

6. The drug according to claim 5, wherein the concentration of bifidobacterium breve b.brevelw01 in the drug is (0.5-1.2) ×10 ⁹ CFU/100μL。